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SEROPREVALENCE OF VARICELLA ZOSTER ANTIBODIES AMONG CHILDREN
WITH MALNUTRITION, MALIGNANCIES AND HIV INFECTION
B. ADMANI, W.M. MACHARIA and F. WERE
ABSTRACT
Objective: To determine the seroprevalence of varicella zoster in paediatric patients
at a high risk of developing complications.
Design: A cross-sectional study.
Setting: Paediatric general wards at Kenyatta National Hospital.
Subjects: Children with malignancies, severe malnutrition and were HIV positive.
Interventions: The sample size was calculated at 147 subjects. Venous samples were
tested for varicella zoster virus (VZV) antibodies using enzyme immunosorbent
assay (ELISA) technique at Kenya Medical Research Institute (KEMRI) laboratories,
The data were anaIysed using the SPSS software and presented in form of tables
and graphs. The prevalence of VZV antibodies was determined and 95% conﬁdence
interval computed.
Results: The overall seroprevalence of VZV antibodies in the three groups of children
studied was 23.6% (95% CI= 17.4, 29.8), The seroprevalence of VZV antibodies in those
with malignancies and severe malnutrition was 24.1 and 25.0% respectively. About
22% of HIV positive children had protective levels of VZV antibodies. Though the
seroprevalence increased with age, it was not signiﬁcantly associated with area of
residence, size of residence, family size or income.
Conclusions: The low prevalence of protective VZV antibodies among children with
severe malnutrition, malignancies and HIV infection children at Kenyatta National
Hospital warrants routine immunisation of the high-risk population.
INTRODUCTION
Varicella ﬁrst became prominent in Europe during
the sixteenth century and was called chickenpox in
1694 and varicella by Vogel in 1765 (1). Varicella zoster
virus is the aetiologic agent of two human diseases,
varicella and herpes zoster (2).
There is considerable interest in the disease due
to epidemiological variations between geographic
locations, especially between temperate and tropical
regions of the world. Whereas in temperate countries,
varicella is considered to be a childhood disease with
almost universal seroconversion by early adolescence,
in tropical countries, it is both a childhood and
adulthood disease (3,4).
There is very scanty information on
seroprevalance of VZV in Africa, and most of the
information on tropical countries has come from
Central America and South East Asia (4-6).

Immuno-compromised patients are at
signiﬁcantly higher risk of developing varicellaassociated morbidity and mortality than their
immuno-competent counterparts (7). Malignancies,
malnutrition and HIV disease cause
immuno-suppression, mainly affecting cell-mediated
immunity. There appears to be some association
between recovery from disease in the immunocompromised and a brisk VZV-speciﬁc cell-mediated
immune response, as indicated by lymphocyte
blastogenesis or lymphocyte-mediated cytotoxicity
at the time of initial evaluation. These patients have a
mortality rate ranging from seven to 20% with a very
high incidence of visceral dissemination (8-11).
An attack of varicella induces both cellular and
humoral immune responses to VZV. Although the
presence of either may be used to indicate immunity
to varicella, this is most frequently determined by
measuring the humoral response. The tests used
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include complement ﬁxation, neutralisation, immune
adherence haemagglutination, ﬂuorescent antibody
to membrane antigen (FAMA), radioimmunoassay,
and enzyme-linked immuno-sorbent assay (ELISA).
The ELISA technique is relatively simple and the
laboratory equipment required is minimal with
sensitivity of about 97% and speciﬁcity of 94%. A live
attenuated varicella vaccine has been developed and
is immunogenic with a good safety proﬁle in both
healthy and high-risk individuals (12).
There are concerns about safety and
efﬁcacy in the use of live attenuated vaccines in
immunocompromised patients particularly those
with AIDS. Data from the 1999 Paediatric AIDS
Clinical Trial Group indicated that the vaccine was
immunogenic, effective and safe.
Chickenpox is thus an important cause of
morbidity and mortality in immuno-compromised
patients. Although this group of patients would
beneﬁt from the vaccine, the cost may make it
impossible for all of them to be vaccinated. This study
aims at determining the seroprevalence of varicella
in the high-risk children population as an indicator
of its susceptibility to the infection.
MATERIALS AND METHODS
The study objective was to determine the
seroprevalence of varicella-zoster antibodies in
children with malignancies, severe malnutrition and
HIV infection at Kenyatta National Hospital.
This was a hospital based cross-sectional study
carried out in paediatric general wards at Kenyatta
National Hospital. KNH is the national tertiary
hospital and teaching hospital for the University
of Nairobi, Faculty of Medicine. It is also the main
in-patient hospital for the low and middle - income
society in Nairobi and its environments. There are
four paediatric general wards at the hospital and each
of these wards admits approximately 30-50 patients
daily.
Case deﬁnition:
(i) Malignancy: based on bone marrow cytology for
leukemia, ﬁne needle aspirate or a biopsy for
lymphoma and biopsy for solid tumours.
(ii) Severe malnutrition: deﬁned using Wellcome
classiﬁcation as children less than 80% of the
expected body weight with oedema or less than
60% of expected body weight with or without
oedema.
(iii) HIV positivity: based on positive ELISA results
for HIV infection.
Study population: All children who fulﬁlled the criteria
outlined below were selected consecutively.
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Inclusion criteria:
(i) Age between one to 12 years accompanied by
either parent or guardian.
(ii) Diagnosed with malignancy using predeﬁned
criteria.
(iii) Diagnosed with severe malnutrition.
(iv) HIV positive children diagnosed using ELISA.
(v) Written consent by a parent or guardian before
recruitment to the study.
Exclusion criteria:
Sample size was computed for each of the three
groups, that is, children with malignancies, those
with severe malnutrition and HIV positivity. This was
done to give the study enough power to sub-analyse
besides computing the overall prevalence.
The sample size was determined as follows
n=(Z1-α/2)2P(1-P)/δ2
Where:
n = minimum sample size
Z1-α/2 =
the table value for standard normal
distribution at 5% signiﬁcance level =
1.96
δ
=
degree of precision = 10%
α
=
signiﬁcance level set at 5%
p
=
estimated prevalence of children with VZV
antibodies.
P was estimated from studies carried out
in West Indies, Singapore, Phillipines and
Western India where the prevalence of
children with protective antibodies against
varicella ranged from 10 to 20%, therefore
a mean of 15% was used.
n
=
1.962 X 0.15 x 0.85/0.12
=
49 was the minimum sample size for each
of the three groups involved.
Study procedure:
Clinical procedures: The investigator visited the
paediatric general wards daily from 8:00am to
12:00pm and consequently identiﬁed eligible patients
by going through the patients’ clinical records. The
primary diagnosis was conﬁrmed to make sure it
conformed to the case deﬁnition and the patient
fulﬁlled the inclusion criteria.
After obtaining an informed written consent,
a structured questionnaire, was then administered.
Information collected included age, sex, previous
admissions, size of family, number of rooms in the
house and monthly family income. The patients were
recruited consecutively in until they reached the
minimum sample size for each of the three groups.
A venous sample of 2ml was obtained in a sterile
procedure and 30 minutes allowed for clotting.
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(SPSS). The seroprevalence of VZV antibodies was
determined and 95% conﬁdence interval levels
(CI) computed, to get the proportion of children
with protective antibodies, that is, immune status
ratio of greater than 0.9, for both the overall study
population and each of the groups deﬁned by the
primary diagnosis. Descriptive statistics including
age, sex, area of residence, size of family, size of
houses, monthly income and previous admissions
were determined and used to describe the sociodemographic characteristics of the study population.
For categorical variables the chi-square test was used
and P<0.05 was used for signiﬁcance.

Serum was then extracted and placed into plastic
vacutainers. Serum samples were then transferred to
KEMRI laboratories immediately where they were
stored at -20°C until tested.
Laboratory procedures: VZV antibodies were measured
by enzyme linked immuno-sorbent assay (ELISA)
used to measure VZV speciﬁc IgG. This was done at
KEMRI laboratories. A commercial kit by the name of
Trinity Biotech Captia VZV IgG ELISA, which has a
sensitivity of 97% and a speciﬁcity of 94% compared
against ﬂuorescent antibody to membrane antigen
assay as the standard. For each serum sample tested,
immune status ratio (ISR) value was calculated by a
formula provided by kit manufacturers using optical
density against the cut-off value. Value of greater
than 0.9 were considered negative and indicated
susceptibility to VZV infection.

RESULTS
Data were collected in August and September 2003.
The study population consisted of 182 children whose
age ranged from one to 12 years with a mode of 1-4
years. The demographic characteristics of the study
population are shown in Table 1.

Ethical consideration: Permission to carry out the study
was sought from the KNH Research and Ethical
Committee. There was no cost incurred by the parent
or guardian in the transport or processing of the serum
specimen. An informed written consent was taken
from the parent/guardian of the children enrolled
in the study and they were given an appointment
when the results were to be made available to them.
If the child was found to be susceptible to chickenpox,
he/she was offered varicella-zoster vaccine at no cost
to the parents.

Seroprevalence of VZV: The overall prevalence of
protective varicella zoster antibodies was found to be
23.6% (95% C I; 17.4-29.8). The prevalence of protective
VZV antibodies in children with malignancies was
found to be 24.1 % (95% Cl; 13.3- 34.9), whereas in
those with severe malnutrition it was 25.0% (95% CI;
14.1- 36.0). HIV positive children had a seropositivity
rate of 21.9% (95% Cl 11.8-32.0). Seropositivity of VZV
increased signiﬁcantly with age, with 17.5% of one to
four year old children being seropositive as compared
to 38.3% in children between the ages of eight and 12
years (p = 0.012), (Table 2 and Figure 1).

Analysis and data management: Data obtained were
entered into the computer and analysed using
the statistical package for social sciences software

Table 1
Socio-demographic characteristics of study population
Severe malnutrition
No.
(%)
Sex
Age
(years)

Area of
residence
Monthly
income per
month (ksh)

Male
Female
Total
1-4
4-8
8-12

31
29
60
42
18
-

Total

60

Within Nairobi
Outside Nairobi

44
16

Total

60

<2000
2000-5000
>5000

44
16
-

Total

60

52
48
64
70
30
19

Primary diagnosis
HIV positive
No.
(%)
35
29
58
26
19
29.7

54.7
45.3
182
40.6
29.7
23

64
73.3
26.7

37
27

57.8
42.2

52
11
1.6
64

65.5
34.5

104
78

19
16
39.7

32.7
27.5
42

82
53

19
39

182
32.8
67.2

58
81.3
17.2
2

Total

38
20

58

64
73.3
26.7
1

Malignancy
No.
(%)

35
21
3.4
58

100
82
182

60.3
36.2
3

144
35
182
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Continuation of Table 1
Number of
siblings

Previous
hospital
admission
Number of
rooms

1
2
3
4
>4

8
20
18
9
5

13
33.3
30
15
8.3

16
35
4
6
3

25
54.7
6.3
9.4
4.7

Total

60

Yes
No

13
47

21.7
78.3

22
42

34.4
65.6

Total

60

64

58

182

1
2-4
>4

40
16
4

66.7
26.7
6.7

44
19
1

68.8
29.7
1.6

Total

60

64

7
31
9
7
4

12.1
53.4
15.5
12.1
6.9

58

64

31
86
31
22
12
182

17
41

29.3
70.7

52
130

45
10
3

77.6
17.2
5.2

129
45
8

58

182

Table 2
Age related seroprevalence of VZV antibodies
Age (years)

1< 4
4< 8
8<12

Seropositive

Seronegative

Total

No.

(%)

No.

(%)

No.

(%)

15
11
17

17.2
20.8
40.5

72
42
25

82.8
79.2
59.5

87
53
42

100
100
100

43

139

182

100

Total
X2 = 8.816; P = 0.012

Table 3
Relationship between seroprevalence and socio-demographic characteristics
Socio-demographic characteristic

Gender

Previous hospital
admissions
Area of residence

Monthly family income

Seropositive

Seronegative

No.

(%)

No.

(%)

Male
Female

24
19

23.1
24.4

80
59

76.9
75.6

Total

43

Yes
No

16
27

Total

43

Nairobi
Outside Nairobi

24
19

Total

43

<2000
2000-5000
>5000

28
14
1

Total

43

139
30.8
20.8

36
103
76
63

69.2
79.2

103
34
2
139

104
78

0.840

52
136

0.151

182
76
76.8

139
21.4
29.2
33

P-value

182

139
24
23.2

Total

100
82

0.896

182
78.6
70.8
67

131
48
3
182

0.519
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Continuation of Table 3
Number of siblings

1
2
3
4
>4

6
20
8
6
3

Total

43

Number of rooms in the 1
house
2-4
>4
Total

29
12
2

19.4
23.3
25.8
27.3
25
22.5
26.7
25

43

Per cent of seropositive children

40

30

20

10

4<8
Age (years)

80.6
76.7
74.2
72.7
75

139

Figure 1
Age related seroprevalence of VZV

1< 4

25
66
23
16
9

8<12

There was no statistically signiﬁcant difference in the
seroprevalence of VZV in children by gender, previous
hospital admissions, area of residence, monthly family
income, number of siblings and number of rooms in
the houses they resided in (Table 3).
DISCUSSION
This study revealed a very low overall prevalence of
protective antibodies to VZV in all the three groups
of children studied (23.6%), which mirrored that of
many other countries in the tropics and less than
those in the temperate countries. Various studies
carried out in Thailand and Philippines showed the
seroprevalence of VZV antibodies ranging between
20% and 30% (3), while studies in West Indies, India
(Velore) and Singapore showed a seroprevalence of
less than 10% in children (13).
In temperate countries, the prevalence of
protective VZV antibodies is much higher. In
surveys carried out in the United States of America,
seroprevalence of VZV antibodies in children was
more than 90% (3). Similar results were seen in studies
carried out in Germany (13).
This study showed a seroprevalence of 24.1%
in children with malignancies. A study conducted in

100
33
6
139

31
86
31
22
12

0.966

182
77.5
73.3
75

129
45
8

0.847

182

Yaounde, Cameroon on immunity to VZV in children
with leukemia showed a seropositivity rate of 34%,
whilst in Denmark; a seropositivity rate of 37% was
found. A study in Israel to compare antibodies to
VZV in children with Hodgkin’s disease and healthy
children found the difference not to be statistically
signiﬁcant (14).
The seroprevalence of VZV antibodies in
children with HIV was found to be 21.9%. This
correlates well with other studies conducted in
Eritrea where and overall seropositivity rate was
44% (5). This difference was thought to be due to the
fact that the Eritrean study included adults as well.
Other studies on children with HIV in Connecticut,
USA showed 28% of the children were susceptible
to varicella (7). In Madrid, Spain, a study conducted
on HIV positive children admitted at a hospital
showed 20% of the children were susceptible to VZV
(10). There seems to be no signiﬁcant difference in
the prevalence of varicella infections between HIV
positive children and their healthy counterparts.
This was conﬁrmed by a comparative study on the
prevalence of VZV in conjunctiva of HIV positive
and healthy children in Canada, which showed no
signiﬁcant difference (15).
In severely malnourished children the
seroprevalence of VZV antibodies was found to be
25%. No studies have been conducted elsewhere
to compute the susceptibility to varicella in this
population, though it is postulated to reﬂect that in
the general population.
The differences in seroprevalence of VZV
antibodies in temperate and tropical countries have
been thought to be due to the weather differences. The
year long high temperature, humidity, and absence
of human clustering during winter are thought to
reduce transmission rate (13). It is thought that high
ambient temperature and humidity in the tropics
decreases VZV transmission by inactivating the
virus in the cutaneous lesions. Alternatively, it is
possible that because of high prevalence of certain
other childhood viruses in tropical countries, there
is interference with the transmission of VZV and the
age of varicella infection is postponed (16).
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This study showed a seropositivity rate of
23.1% and 24.4% for males and females respectively.
This difference between the seroprevalence of VZV
antibodies between males and females was not
statistically signiﬁcant (p=0.840). This observation was
in keeping with the ﬁndings of studies in Sao Paulo,
Brazil and Thailand, which showed a seroprevalence
of 49.4% and 55.2% in males and females respectively, a
difference that was not statistically signiﬁcant (16).
This study showed a gradual increase in
the seropositivity rate of VZV antibodies in
immunocompromised children between one year of
age and 12 years, with seropositivity increasing from
17.2% to 40.5% in 1-4 years to 8-12 years respectively.
This difference was statistically signiﬁcant (p = 0.012).
This observation was in keeping with other studies
from West Indies, Singapore, and Thailand (3). In India,
the age related seroprevalence rate of VZV antibodies
was 29% in the age group of 1-5 years, 51.1% in 5-10
years and 71% in 11-15 years (4). A study in Thailand
showed a seroprevalence of 20% in children aged
between 1-4 years, which increased to 70% above the
age of 15 years. In Singapore, VZV seroprevalence
was noted to be 30% in children aged 1-5 years and
56.7% in children aged 11-15 years (3). A study in UAE
showed a seroprevalence of 45.8% in children less than
10 years and 68% in those aged less than 20 years, a
difference, which was statistically signiﬁcant (17).
These ﬁndings are thought to be due to the fact that as
children grow, they tend to have more exposure to VZV
thus more chances of developing the disease. Varicella
is considered a pre-school disease in countries with
temperate climates and a childhood and adulthood
disease in tropical areas. This is attributed to the year
long high temperature and humidity, and the absence
of human clustering during winter.
There was a slightly increased albeit not
statistically signiﬁcant seropositivity of VZV antibodies
in children who had been admitted previously (30.8%)
as compared to those not previously admitted at KNH
(20.8%) (p = 0.151). An increase in seropositivity in
children with a history of previous hospital admissions
was anticipated due to exposure to varicella whilst
in the wards and the effects of human clustering as
it happens in institutions.
In this study, children living within Nairobi,
which is an urban area, had a seroprevalence of 24.0%
and those living outside Nairobi had a seroprevalence
of 23.2%. This difference was not statistically
signiﬁcant (p = 0.896). Epidemiological comparisons
between rural and urban populations have been
documented in West Bengal, India, where nearly all
adults in the urban area were immune and all rural
adults were susceptible to varicella infection (16). A
study in Thailand showed no signiﬁcant difference
in the overall seroprevalence of VZV between rural
and urban population, but in southern states of the
country, the seroprevalence was signiﬁcantly lower
in rural areas (16). This ﬁnding was thought to be due
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to high population densities in urban areas, which
may partially overcome the transmission-interrupting
effect of a tropical climate. This phenomenon was not
evident in our study probably due to the fact that the
population density of Nairobi is much less than that of
the city of Calcutta, West Bengal and the temperature
and humidity in Nairobi is markedly lower than
those encountered in Calcutta where the highest
temperatures are about 38°C. These differences blunt
the effect of urban living in the transmission of VZV
as was seen in the northern states of Thailand.
There was a slight increase in the seropositivity
of VZV antibodies in children who came from families
with a higher monthly income (33.3%), as compared
to those from a lower monthly income (21.4%).
This difference was not found to be statistically
signiﬁcant (p= 0.519). These results mirrored those
in Eritrea, where a tribe called the Rashaida, which
has a low socio-economic status, was found to have
a signiﬁcantly lower seroprevalence than the rest
of the population (5). In Israel though, in children
with Hodgkin’s disease, no statistical difference
was found in the seroprevalence of VZV antibodies
between those children from afﬂuent backgrounds
and those of a lower socio-economic status (14).
These differences in the seroprevalence between
children of different socio-economic backgrounds
as seen in some studies is thought to be due to the
fact that children from richer families tend to go to
schools earlier, are then exposed to the virus earlier
with clustering in classrooms making transmission
easier.
This study showed that the number of rooms
in houses the children living in did not make a
signiﬁcant difference in the seroprevalence of VZV
(p = 0.847). This ﬁnding was surprising as children
living in smaller houses were expected to have a
higher seropositivity rate due to enhanced clustering
and thus transmission of VZV.
This study showed a VZV seropositivity rate
of 27.3% in children who lived in families with four
children as compared to 19.4% in those with one
child. This difference was not statistically signiﬁcant
(p = 0.966). It was thought that larger families would
enhance early exposure and transmission of varicella,
which is a highly infectious disease with secondary
infection rate of 90-100%. In our set-up though, this
factor does not seem to be playing a signiﬁcant role
in transmission mechanics of VZV.
Illnesses like severe malnutrition, malignancies,
use of chemotherapy for the treatment and HIV
infection cause immuno-suppression by affecting
the cell-mediated immunity. A study conducted by
Gershon et al (18) showed that there is an association
between recovery from varicella infection in the
immuno-compromised and a brisk VZV-speciﬁc
cell-mediated immune response.
Patients with malignancies receiving anticancer
therapy at St. Judes Children Research Hospital
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were found to have visceral dissemination in 32%
after VZV infection, and had a mortality rate of
seven (7%). A study at Sizwe Tropical Hospital in
Reinfontein, South Africa showed a mortality rate
of 43% in children with HIV disease who developed
chickenpox (18).
These complications could be prevented using
a live-attenuated varicella vaccine. This is a highly
immunogenic vaccine with a seroconversion rate
ranging from 92.2% to 98.7% in healthy children and
83.7% to 92.1% in children with underlying disease
(19, 20). It has also shown to have 98% vaccine
efﬁcacy.
The vaccine is indicated for all healthy
individuals older than 12 months, who are susceptible
to varicella, seronegative children who are at high
risk of complications, such as patients undergoing
chemotherapy, severe malnutrition and HIV positive
children. It is also indicated for susceptible women of
childbearing age to prevent foetal varicella syndrome
and in closed societies like institutions.
In developing countries it is not feasible to
recommend vaccination of all children. Since
the cost of the vaccine is more than the average
monthly income of majority of families in the study
population, it would only be practical to vaccinate
the immunocompromised patients since the risk of
mortality and morbidity is the highest in this group.
Given that the seroprevalence of VZV ranges from
17.2% to 40.5% in 1-4 years to 8-12 years old children
respectively, it would be appropriate to vaccinate
immunocompromised patients soon after one year
of age or on ﬁrst contact. It is hoped that this study
will contribute to the prevention of chickenpox in
this high-risk population.
In conclusion, we found overall prevalence of
protective VZV antibodies (23.6%) among children
with HIV infection, severe malnutrition and
malignancies admitted at KNH paediatric wards to be
relatively low. This was comparatively lower than the
seroprevalence in countries with temperate climates
and mirrors the situation in other tropical countries.
The prevalence of protective VZV antibodies was
not dependent on sex, area of residence, family size,
family income, previous admissions but increases
signiﬁcantly with advancing age (p = 0.012).
Vaccination of children with malignancies,
severe malnutrition and HIV infection at Kenyatta
National Hospital against varicella-zoster is highly
recommended so as to reduce morbidity and mortality
from varicella in this high- risk population.
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